Prospective evaluation of the effect of short-term oral vitamin D supplementation on peripheral neuropathy in type 2 diabetes mellitus

Medical Principles and Practice

Volumn 24, Issue 3, 2015, Pages 250-256

  Shehab, D ^a   Al Jarallah, Khaled ^a   Abdella, Nabila ^a   Mojiminiyi, Olusegun A ^a   Al Mohamedy, Hisham ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MUBARAK AL KABEER HOSPITAL   (Kuwait)

Author keywords

Clinical trial; Peripheral neuropathy; Type 2 diabetes; Vitamin D

Indexed keywords

CALCITRIOL; COLECALCIFEROL; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC PERIPHERAL NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; NEUROPATHY DISABILITY SCORE; NEUROPATHY SYMPTOM SCORE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SERUM; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; CLINICAL TRIAL; COMPLICATION; DIABETIC NEUROPATHIES; DIET SUPPLEMENTATION; DISABILITY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHOLECALCIFEROL; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIETARY SUPPLEMENTS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84929955810     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000375304     Document Type: Article

References (23)

1. Edwards JL, Vincent AM, Cheng HT, et al: Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120: 1-34.
2. Chaychi L, Mackenzie T, Bilotta D, et al: Association of serum vitamin D level with diabetic polyneuropathy. Med Pract Rev 2011; 2: 11-15.
3. Shehab D, Al-Jarallah K, Mojiminiyi OA, et al: Does vitamin D deficiency play a role in peripheral neuropathy in type 2 diabetes Diabet Med 2012; 29: 43-49.
4. Soderstrom LH, Johnson SP, Diaz VA , et al: Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001-2004 NHANES. Diabet Med 2012; 29: 50-55.
5. Valensi P, Devehat C, Richard J, et al: A multicenter double blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy: a preliminary report. J Diabetes Complications 2005; 19: 247-253.
6. Lee P, Chen R: Vitamin D as an analgesic for patients with type 2 diabetes and neuropathic pain. Arch Intern Med 2008; 168: 771-772.
7. Bell DS: Reversal of the symptoms of diabetic neuropathy through correction of vitamin D deficiency in a type 1 diabetic patient. Case Rep Endocrinol 2012; 2012: 165056.
8. Standards of Medical Care in Diabetes 2013. Diabetes Care 2013; 36(suppl 1):S11-S66.
9. Young MJ, Boulton AJ, Macleod AF, et al: A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
10. Abbott CA, Carrington AL, Ashe H, et al: The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19: 377-384.
11. Malik RA, et al: Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia 2003; 46: 683-688.
12. Kimura J: Principles of nerve conduction studies; in Kimura J (ed): Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice, ed 2. Philadelphia, Davis, 1989, pp 78-102.
13. Kimura J: Principles and pitfalls of nerve conduction studies. Ann Neurol 1984; 16: 415-428.
14. Shehab D: Normative DATA of nerve conduction studies in the upper limb in Kuwait-are they different than the Western data Med Princ Pract 1998; 7: 203-208.
15. Shehab D, Moussa MA: Normal values of lower limb nerve conduction in Kuwait. II. Med Princ Pract 1999; 8: 134-137.
16. Adams JS, Hewison M: Update in vitamin D. J Clin Endocr Metab 2010; 95: 471-478.
17. Holick MF, Binkley N, Bischoff-Ferrari HA, et al: Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930.
18. Plotnikoff GA, Quigley JM: Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78: 1463-1470.
19. Carlson AN, Kenny AM: Is vitamin D insufficiency associated with peripheral neuropathy Endocrinologist 2007; 17: 319-325.
20. Neveu I, Jehan F, Wion D: Alteration in the levels of 1, 25-(OH)2D 3 and corticosterone found in experimental diabetes reduces nerve growth factor (NGF) gene expression in vitro. Life Sci 1992; 50: 1769-1772.
21. Riaz S, Malcangio M, Miller M, et al: A vitamin D 3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozocinp diabetic rats. Diabetologia 1999; 42: 1308-1313.
22. Fukuoka M, Sakurai K, Ohta T, et al: Tacalcitol, an active vitamin D 3 , induces nerve growth factor production in human epidermal keratinocytes. Skin Pharmacol Appl Skin Physiol 2001; 14: 226-233.
23. Anand P, Terenghi G, Warner G, et al: The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996; 6: 703-707.